Literature DB >> 31913090

Cognitive functions in pediatric multiple sclerosis: 2-years follow-up.

Zeynep Öztürk1, Kıvılcım Gücüyener2, Şebnem Soysal2, Gökçen Düzgün Konuşkan3, Bahadır Konuşkan3, Asiye Uğraş Dikmen4, Banu Anlar3.   

Abstract

Objective: To assess the neuropsychological status of pediatric multiple sclerosis (MS) patients and its relationship with clinical variables in a longitudinal study.
Methods: Patients with MS (n = 46) and age- and gender-matched healthy control subjects (HCs, n = 53) were given tests of non-verbal reasoning, attention/concentration, visuospatial judgement and verbal fluency at baseline visit and after 2 years of follow-up. Cognitive impairment was defined as a failure on at least three of the four tests. Patients were grouped according to the age of disease onset (≤12 years as group 1 and > 12 years as group 2).
Results: Cognitive impairment was detected in 22 of 46 patients at follow-up (47.8%). Patients with cognitive worsening had higher EDSS scores at follow-up compared to cognitively improved/stable group (0.68 ± 1.16 vs 0.04 ± 0.2, p = 0.01). The most affected domains were attention/concentration and non-verbal reasoning. Comparison between baseline and follow-up tests showed impairment in non-verbal reasoning over time in group 1 patients while other functions improved over time in patient and control groups as expected.
Conclusion: Pediatric MS is likely to affect patients' cognition concurrently with their disability levels. This effect is significant in the non-verbal reasoning area in patients with disease onset before age 12 years. A practical method assessing this function should be part of these patients' regular follow-up for optimal treatment, prevention and rehabilitation.

Entities:  

Keywords:  Multiple sclerosis; attention/concentration; cognitive; non-verbal reasoning; verbal fluency; visuospatial judgement

Mesh:

Year:  2020        PMID: 31913090     DOI: 10.1080/01616412.2019.1710417

Source DB:  PubMed          Journal:  Neurol Res        ISSN: 0161-6412            Impact factor:   2.448


  2 in total

1.  Fingolimod as first-line treatment in pediatric-onset multiple sclerosis: a case report.

Authors:  Marco Capobianco; Antonio Bertolotto; Simona Malucchi
Journal:  Neurol Sci       Date:  2021-03-12       Impact factor: 3.307

Review 2.  Quantitative Meta-analyses of Cognitive Abilities in Children With Pediatric-onset Multiple Sclerosis.

Authors:  Elena S Lysenko; Mariia D Bogdanova; Marie Arsalidou
Journal:  Neuropsychol Rev       Date:  2022-07-08       Impact factor: 7.444

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.